Compare EXAS & GFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXAS | GFS |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 18.5B |
| IPO Year | N/A | 2021 |
| Metric | EXAS | GFS |
|---|---|---|
| Price | $101.91 | $36.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 10 |
| Target Price | ★ $77.94 | $40.80 |
| AVG Volume (30 Days) | 4.9M | ★ 5.5M |
| Earning Date | 02-18-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,082,033,000.00 | ★ $6,791,000,000.00 |
| Revenue This Year | $19.40 | $1.14 |
| Revenue Next Year | $13.51 | $6.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.47 | 0.25 |
| 52 Week Low | $38.81 | $29.77 |
| 52 Week High | $102.66 | $47.69 |
| Indicator | EXAS | GFS |
|---|---|---|
| Relative Strength Index (RSI) | 85.29 | 49.17 |
| Support Level | $101.45 | $35.32 |
| Resistance Level | $102.00 | $35.98 |
| Average True Range (ATR) | 0.39 | 1.00 |
| MACD | -1.26 | -0.31 |
| Stochastic Oscillator | 88.69 | 19.05 |
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and employs about 13,000 people.